Summary:
Accessibility to CAR-T is limited by traditional manufacturing, with its associated challenges and high cost. Moffitt Cancer Center's Chief BioEngineering Officer, Dr Greg Sawyer, highlights Moffitt's progress in enhancing T cell potency and boosting efficacy through engineering strategies. Dr Sawyer also discusses assays enabling precise assessment of T cell potency and developments in manufacturing, and the resulting impact on scalability and efficiency.This presentation comes from the March 2025 Immuno-Oncology 360º Summit. For more information, go to IO360summit.com.
